MedEquities Realty Trust Gets a Buy Rating from Cantor Fitzgerald

Cantor Fitzgerald analyst Joseph France maintained a Buy rating on MedEquities Realty Trust (NYSE: MRT) today and set a price target of $13. The company’s shares opened today at $10.66.

France wrote:

“Updating 2018-19 outlook. Our new 2018 estimates reflect a slightly lower acquisition pace and are revenue of $70 million (vs. prior $71 million), FFO of $1.19 (vs. prior $1.21) and AFFO of $1.20 (vs. prior $1.22). Our 2019 estimates are revenue of $72 million (vs. $73 million FactSet consensus), FFO of $1.26 (vs. $1.26 consensus) and AFFO of $1.29 (vs. $1.21 consensus).”

According to TipRanks.com, France is a 4-star analyst with an average return of 9.9% and a 55.5% success rate. France covers the Services sector, focusing on stocks such as Cross Country Healthcare, Five Star Quality Care, and Envision Healthcare.

MedEquities Realty Trust has an analyst consensus of Strong Buy, with a price target consensus of $12.75.

See today’s analyst top recommended stocks >>

MedEquities Realty Trust’s market cap is currently $334.3M and has a P/E ratio of 16.66. The company has a Price to Book ratio of 0.96.

Based on the recent corporate insider activity of 20 insiders, corporate insider sentiment is negative on the stock.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

MedEquities Realty Trust, Inc. operates as a real estate investment trust. It focuses on investment in healthcare properties and healthcare related real estate debt investments. It owns, develops, operates, leases, and disposes healthcare properties and portfolios. The company was founded in April 23, 2014 and is headquartered in Nashville, TN.